Study Overview
A new randomized clinical trial from the DIPLOMA-2 study evaluated how patients recover after minimally invasive pancreatoduodenectomy (MIPD) compared with open pancreatoduodenectomy (OPD). Pancreatoduodenectomy, also known as the Whipple procedure, is a major operation used to remove tumors in the head of the pancreas or the periampullary region, an area where the pancreas, bile duct, and small intestine meet. Because this surgery is complex and physically demanding, recovery can be slow even after the patient leaves the hospital.
The main question in this analysis was whether the benefits of minimally invasive surgery continue after discharge. Rather than relying only on clinic visits or patient reports, the investigators used wearable activity trackers to measure step count, active minutes, and heart rate variability over the first 90 days after surgery.
Why This Matters
Surgeons and patients often focus on the early hospital recovery period, but real-life recovery continues for weeks or months after discharge. A patient may leave the hospital after a few days yet still feel weak, fatigued, and limited in daily activities. Measuring activity after discharge provides a more complete picture of recovery.
Minimally invasive surgery is designed to reduce surgical trauma, pain, and inflammation compared with open surgery. In theory, that should help patients move more, recover faster, and experience less physiologic stress. However, until now it has been unclear whether these advantages remain measurable beyond the hospital stay, especially after a major operation such as pancreatoduodenectomy.
Study Design and Participants
The DIPLOMA-2 trial was an international, multicenter, patient-blinded randomized clinical trial conducted between 2022 and 2023 in 14 high-volume centers across 6 European countries. Patients with a suspected or proven upfront resectable neoplasm in the pancreatic head or periampullary region were included, meaning the tumors were considered removable without vascular contact.
A total of 288 patients were included in this analysis. The average age was 68.3 years, and 58.3% were men. Patients were randomly assigned in a 2:1 ratio to undergo either MIPD or OPD. Activity tracker data were available for 236 patients, which is 82% of the total group.
Each participant wore a Fitbit Inspire 2 starting 2 weeks before surgery and continuing until 90 days after surgery. This allowed the research team to compare baseline activity before the operation with recovery patterns afterward.
What the Activity Tracker Measured
The wearable device recorded three key markers:
1. Step count: a simple measure of how much the patient walked each day.
2. Active minutes: time spent in meaningful physical movement.
3. Heart rate variability (HRV): the small variation in time between heartbeats. Higher HRV generally reflects better parasympathetic nervous system activity, which is associated with relaxation, recovery, and lower physiological stress.
HRV is increasingly used in recovery research because it can provide insight into how the body is responding to surgery, even when a patient may not feel major differences subjectively.
Main Findings
The researchers found that patients who underwent minimally invasive surgery had a better recovery profile in the first several weeks after surgery.
By postoperative day 30, compared with the open surgery group, patients in the MIPD group:
– took 659 more steps per day on average,
– spent 22 more minutes per day in active movement,
– and had HRV that was 9 milliseconds higher.
These differences were statistically significant, suggesting that the recovery advantage of minimally invasive surgery was real and not likely due to chance.
By postoperative day 90, the two groups had similar step counts and active minutes. In other words, the early mobility advantage of minimally invasive surgery had largely disappeared by 3 months. However, HRV remained higher in the MIPD group, suggesting that physiologic recovery and lower stress may persist even after visible activity levels have normalized.
The timing analysis also showed that patients after MIPD had a significantly higher step count from postoperative days 16 to 39 and more active minutes from days 14 to 37. This suggests that the main advantage in physical activity was concentrated in the first 3 to 5 weeks after surgery.
Interpretation of the Results
These findings support the idea that minimally invasive pancreatoduodenectomy can help patients regain activity sooner after major pancreatic surgery. The benefits were modest but meaningful, especially during the early recovery period when patients are often struggling with pain, fatigue, reduced appetite, and deconditioning.
The persistent HRV advantage at 90 days may indicate that the body continues to recover more completely after minimally invasive surgery, even when walking activity appears similar between groups. This could reflect less surgical inflammation, less disruption of tissues, or a faster return of autonomic balance.
Still, it is important to interpret these results in context. A difference of several hundred steps per day or about 20 extra active minutes is helpful, but it does not mean that MIPD eliminates recovery challenges. Pancreatoduodenectomy remains one of the most difficult abdominal operations, and patients still need structured follow-up, nutrition support, pain control, and gradual rehabilitation.
Clinical Meaning for Patients and Surgeons
For patients, the study suggests that minimally invasive surgery may offer an earlier return to everyday movement after discharge. That can matter in practical ways: walking more, feeling less physically drained, and potentially regaining independence sooner.
For surgeons and care teams, the results reinforce the value of enhanced recovery pathways after pancreatic surgery. They also show that wearable technology can provide objective recovery data outside the hospital, which may be more informative than relying only on clinic impressions or patient memory.
However, the benefits were not dramatic, and by 90 days the step-count advantage was no longer present. This means that the choice between minimally invasive and open surgery should still depend on overall surgical suitability, tumor features, surgeon expertise, and center experience. A technically difficult minimally invasive operation is not necessarily better if it increases operative risk or compromises oncologic quality.
Strengths and Limitations
This study has several strengths. It was randomized, multicenter, and patient-blinded, which helps reduce bias. It also used continuous wearable monitoring rather than relying solely on self-reported recovery. The international setting increases the relevance of the findings across different surgical systems.
There are also limitations. Activity tracker data were not available for all patients, so some recovery information was missing. Wearables measure movement well but do not capture every aspect of recovery, such as pain, appetite, emotional wellbeing, or return to work. In addition, this study took place in high-volume European centers with experienced teams, so the results may not apply directly to lower-volume hospitals or settings with less specialized pancreatic surgery expertise.
Another important point is that heart rate variability can be influenced by many factors, including sleep, medications, stress, and illness. While higher HRV is generally favorable, it should be interpreted as one part of a broader recovery picture rather than as a standalone marker.
What This Adds to the Evidence
Previous studies of minimally invasive pancreatic surgery have often focused on short-term outcomes such as blood loss, hospital stay, complications, and readmission. This analysis adds a more patient-centered perspective by looking at actual recovery after discharge.
The findings suggest that the early advantage of minimally invasive surgery is not limited to the hospital. Patients moved more for several weeks after the operation and showed lower physiologic stress for up to 3 months. That is important because the period after discharge is when many patients are trying to rebuild strength and adapt to life after cancer surgery.
Practical Takeaway
The main message is straightforward: after pancreatoduodenectomy, minimally invasive surgery appears to support earlier physical recovery and less physiologic stress than open surgery, especially in the first month after the operation. By 90 days, movement levels even out, but the physiologic recovery signal remains stronger in the minimally invasive group.
For patients eligible for either approach, these results provide additional evidence that minimally invasive pancreatoduodenectomy can offer benefits beyond the hospital stay. For clinicians, they highlight the usefulness of tracking real-world activity as a recovery endpoint.
Conclusion
In this predefined analysis of the DIPLOMA-2 randomized clinical trial, minimally invasive pancreatoduodenectomy was associated with increased activity during the first 5 weeks after surgery and lower physiologic stress up to 3 months compared with open surgery. These findings suggest that the recovery benefits of minimally invasive pancreatic surgery extend beyond discharge, although the differences are modest and may depend on surgical expertise and center experience. Further research is needed to determine whether similar benefits are seen in broader practice settings and whether they translate into better long-term patient outcomes.